1. Home
  2. JFIN vs PMN Comparison

JFIN vs PMN Comparison

Compare JFIN & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JFIN

Jiayin Group Inc.

SELL

Current Price

$1.44

Market Cap

71.7M

Sector

Finance

ML Signal

SELL

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

HOLD

Current Price

$3.31

Market Cap

84.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFIN
PMN
Founded
2011
2004
Country
China
Canada
Employees
N/A
N/A
Industry
Finance: Consumer Services
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.7M
84.1M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
JFIN
PMN
Price
$1.44
$3.31
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $42.40
AVG Volume (30 Days)
★ 591.0K
390.1K
Earning Date
11-27-2026
11-12-2026
Dividend Yield
★ 58.39%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.35
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.13
$0.29
52 Week High
$8.83
$27.40

Technical Indicators

Market Signals
Indicator
JFIN
PMN
Relative Strength Index (RSI) 42.39 30.28
Support Level $1.21 $2.78
Resistance Level $1.43 $15.05
Average True Range (ATR) 0.16 1.07
MACD -0.01 -0.06
Stochastic Oscillator 14.85 6.01

Price Performance

Historical Comparison
JFIN
PMN

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Share on Social Networks: